CDNA CareDx, Inc.

CIK 0001217234 29 ready 8-Ks latest April 28, 2026, 7:59 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 29

Latest filing April 28, 2026, 7:59 PM ET

Top materiality 0.90

Event mix earnings ×13 · leadership ×7 · other_material ×4

Sentiment 14 pos · 1 neg · 14 neu

Latest earnings reported 2025-FY

Executive change recent →

Recent 8-K filings for CDNA

Highest-materiality recent filing

CareDx acquires Naveris for $160M; Q1 revenue $118M (+39% YoY), raises 2026 guidance

April 28, 2026, 7:59 PM ET M&A materiality 0.90 positive item 1.01 item 2.02 item 9.01 item 7.01 item 8.01 ◈ Earnings Releases◈ Material Agreements

Upfront cash $160M for Naveris, plus up to $100M in revenue milestones; expands into viral-mediated cancer MRD surveillance.
Q1 revenue $118M (+39% YoY); Testing Services revenue $91M (+48% YoY); GAAP net income $3M vs loss $10M prior year.

Read filing →

April 28, 2026, 7:59 PM ET M&A materiality 0.90 positive item 1.01 item 2.02 item 9.01 item 7.01 item 8.01 ◈ Earnings Releases◈ Material Agreements

CareDx acquires Naveris for $160M; Q1 revenue $118M (+39% YoY), raises 2026 guidance

Upfront cash $160M for Naveris, plus up to $100M in revenue milestones; expands into viral-mediated cancer MRD surveillance.
April 23, 2026, 7:59 PM ET leadership materiality 0.40 neutral item 5.02

CareDx grants Keith Kennedy 48,268 RSUs and PRSUs for expanded CFO role

24,134 RSUs approved; one-third vest 4/6/27, then quarterly over three years.
April 16, 2026, 7:59 PM ET M&A materiality 0.85 positive item 1.01 item 2.02 item 7.01 item 9.01 ◈ Earnings Releases◈ Material Agreements

CareDx sells Lab Products to Eurobio for $170M; Q1 rev up 39% to $118M

Divests Lab Products (IVD kits) to Eurobio Scientific for $170M cash; expected close by end of Q3 2026.
February 25, 2026, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 item 5.02 item 7.01

CareDx Q4 rev $108M +25% YoY, FY25 rev $380M; FY26 guide $420-444M; CFO resigns, Kennedy appointed

Q4 revenue $108M (+25% YoY); full-year revenue $380M (+14%). FY2026 guidance $420-444M.
February 24, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 item 5.02 item 7.01

CareDx Q4 revenue up 25% to $108M, guides FY2026 revenue $420M-$444M; CFO resigns, Kennedy appointed

Full year 2025 revenue $380M (+14% YoY); Q4 revenue $108M (+25% YoY).
January 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

CareDx prelim Q4 revenue ~$108M (+25% YoY); FY25 rev ~$380M (+14%)

Q4 testing services volume ~53,000 (+17% YoY); testing revenue ~$78M (+23%).
December 18, 2025, 6:59 PM ET litigation materiality 0.50 neutral item 8.01 item 9.01

Court preliminarily approves CareDx shareholder derivative settlement with governance reforms

Preliminary approval granted Dec 9 for settlement of Edelman v. Bickerstaff derivative action alleging false testing revenue statements.
December 15, 2025, 6:59 PM ET other materiality 0.25 neutral item 5.03 item 9.01 ◈ Governance Changes

CareDx changes director election standard to majority vote; adopts resignation policy

Board amended bylaws on Dec 12, 2025, switching director election standard from plurality to majority vote.
November 4, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 item 7.01

CareDx Q3 revenue $100.1M (+21% YoY), turns to GAAP net income $1.7M; raises FY guidance

Revenue $100.1M, up 21% YoY; testing services volume ~50,300 (+13% YoY).
October 24, 2025, 7:59 PM ET leadership materiality 0.30 neutral item 5.02

CareDx appoints Suresh Gunasekaran to board of directors effective Oct 22, 2025

Appointed Suresh Gunasekaran as Class II director; he is CEO and President of UCSF Health.
August 6, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 item 5.02 item 7.01

CareDx Q2 adjusted revenue up 14% YoY to $90.5M; narrows FY guidance; appoints new CFO

Q2 adjusted revenue $90.5M (+14% YoY); GAAP revenue $86.7M (-6% YoY) due to $3.8M aged receivable write-off.
June 12, 2025, 7:59 PM ET other material materiality 0.50 neutral item 5.02 item 5.07 item 9.01

CareDx shareholders approve equity plan increase of 1.6M shares at annual meeting

Shareholders voted to amend 2024 Equity Incentive Plan, adding 1,600,000 shares (~3% dilution).
June 3, 2025, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

CareDx completes $50M buyback (5% shares), authorizes new $50M program

Completed $50M repurchase of ~3.03M shares, representing 5% of outstanding common stock.
April 30, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

CareDx Q1 revenue $84.7M (+18% YoY); GAAP net loss narrows to $10.4M; non-GAAP net income $5.4M

Revenue $84.7M (+18% YoY); testing services revenue $61.9M (+15%), volume ~47,100 (+12% YoY).
March 28, 2025, 7:59 PM ET leadership materiality 0.35 neutral item 5.02 item 9.01

CareDx enters amended change-of-control severance deal with CFO Abhishek Jain

CFO Abhishek Jain gets 12 months base salary lump sum, full equity vesting, and target bonus upon qualifying termination 3 months before or 12 months after a change of control.
February 26, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01 item 7.01

CareDx Q4 revenue $86.6M (+32% YoY), FY2025 guidance $365-375M; $50M buyback

Q4 revenue $86.6M (+32% YoY); testing services revenue $63.8M (+37%); volume ~45,500 tests (+14%).
January 13, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 item 7.01

CareDx reports preliminary Q4 revenue up 30% YoY to ~$85.5M; guides 2025 revenue $370M

Q4 revenue expected $85M-$86M, up ~30% YoY; testing services revenue $62.5M-$63.5M, up 35%.
January 8, 2025, 6:59 PM ET other material materiality 0.25 neutral item 5.02 item 9.01

CareDx amends outside director compensation policy, accelerates vesting, drops chair retainer

Annual NSO and RSU awards vest fully on day before next annual meeting if before one-year anniversary.
November 4, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

CareDx Q3 revenue $82.9M (+23% YoY), raises FY guidance to $327-331M with positive EBITDA $6.9M

Revenue $82.9M (+23% YoY); testing services rev $60.8M (+27%); volume 44,600 tests (+16%).
October 15, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 item 7.01

CareDx reports preliminary Q3 revenue of $82-83M, up 23% YoY; testing volume rises 16%

Preliminary Q3 2024 revenue $82-83M, up ~23% YoY; testing services $60-61M (+26%).
October 8, 2024, 7:59 PM ET regulatory materiality 0.75 positive item 8.01

CareDx: DOJ declines to intervene in qui tam, closes investigation; SEC closes probe

On Oct 7, 2024, DOJ notified court it declines to intervene in qui tam filed by former employee; investigation closed.
October 4, 2024, 7:59 PM ET leadership materiality 0.55 neutral item 5.02 item 9.01 ◈ executive_change

CareDx President of Patient and Testing Services Alexander Johnson departs; receives $817,920 in cash severance

Alexander Johnson, President of Patient and Testing Services, separated without cause on Sept 13, 2024.
September 12, 2024, 7:59 PM ET leadership materiality 0.40 neutral item 5.02 item 8.01 item 9.01 ◈ executive_change

CareDx appoints Keith Kennedy COO, Jessica Meng CCO; President Alexander Johnson departs

Keith Kennedy named COO effective Sept 12, 2024; base salary $575,000 plus bonus up to 60%.
July 31, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

CareDx Q2 revenue $92.3M (+31% YoY); raises FY2024 revenue guidance to $320-$328M

Total revenue $92.3M (+31% YoY); Testing Services revenue $70.9M (+33%); volume 43,700 tests (+17%).
June 18, 2024, 7:59 PM ET other material materiality 0.35 neutral item 5.02 item 5.07 item 9.01

CareDx stockholders elect three Class I directors and approve 2024 Equity Incentive Plan

George W. Bickerstaff III, Christine M. Cournoyer, and Hannah Valantine, M.D. elected as Class I directors, terms expiring 2027.
May 9, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

CareDx Q1 revenue $72M (-7% YoY); raises FY2024 revenue guidance to $274-282M

Revenue $72.0M, down 7% YoY from $77.3M but up 10% sequentially from Q4 2023.
April 16, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 item 8.01 item 9.01 ◈ executive_change ×2

CareDx appoints John W. Hanna as President and CEO effective April 15, 2024

John Hanna appointed CEO and Class III director, effective April 15, 2024.
March 11, 2024, 7:59 PM ET leadership materiality 0.55 neutral item 5.02 item 8.01 item 9.01 ◈ executive_change

CareDx appoints Bryan Riggsbee to board as Audit Committee chair, effective March 11

Riggsbee previously CFO of Myriad Genetics (2014–2024) and held senior finance roles at LabCorp and GE.
February 28, 2024, 6:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01 item 7.01

CareDx reports FY2023 revenue $280.3M, exceeding guidance; Q4 net loss includes $96.3M patent accrual

Full-year revenue $280.3M, down 13% YoY; Testing Services revenue $209.7M, down 20%.

Executive changes

Departed

Alexander Johnson

President of Patient and Testing Services

CDNA · CareDx, Inc.

Effective: 2024-09-13
Filed: October 4, 2024, 7:59 PM ET

On September 12, 2024, CareDx, Inc. (the “Company”) announced that the Company reached an agreement with Alexander Johnson, the Company’s President of Patient and Testing Services, pursuant to which Mr. Johnson’s employment would conclude effective as of September 13, 2024 and that such separation would be treated as a termination by the Company without “cause”

Appointed

Keith Kennedy

Chief Operating Officer

CDNA · CareDx, Inc.

Effective: 2024-09-12
Filed: September 12, 2024, 7:59 PM ET

The Board of Directors of CareDx, Inc. (the “Company”) has appointed Keith Kennedy, as the Company’s Chief Operating Officer, effective September 12, 2024 (the “Effective Date”).

Appointed

John W. Hanna

Class III director

CDNA · CareDx, Inc.

Effective: 2024-04-15
Filed: April 16, 2024, 7:59 PM ET

The Board of Directors (the “Board”) of CareDx, Inc. (the “Company”) has appointed John W. Hanna as the Company’s President and Chief Executive Officer and as a Class III director of the Company, in each case effective April 15, 2024 (the “Effective Date”).

Appointed

John W. Hanna

President and Chief Executive Officer

CDNA · CareDx, Inc.

Effective: 2024-04-15
Filed: April 16, 2024, 7:59 PM ET

The Board of Directors (the “Board”) of CareDx, Inc. (the “Company”) has appointed John W. Hanna as the Company’s President and Chief Executive Officer and as a Class III director of the Company, in each case effective April 15, 2024 (the “Effective Date”).

Appointed

R. Bryan Riggsbee

Director

CDNA · CareDx, Inc.

Effective: 2024-03-11
Filed: March 11, 2024, 7:59 PM ET

On March 9, 2024, the board of directors (the “Board”) of CareDx, Inc. (the “Company”) appointed R. Bryan Riggsbee as a Class II director of the Company, effective March 11, 2024.

Earnings & guidance

2025-FY EPS reported -$0.40 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event earnings

14 positive 1 negative 14 neutral

source · CDNA on sec.gov